Compare WT & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WT | VCRE |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2011 | N/A |
| Metric | WT | VCRE |
|---|---|---|
| Price | $19.41 | $11.35 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 5.8K |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 127.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $493,753,000.00 | N/A |
| Revenue This Year | $35.04 | N/A |
| Revenue Next Year | $8.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.43 | N/A |
| 52 Week Low | $10.69 | $11.05 |
| 52 Week High | $21.23 | $12.85 |
| Indicator | WT | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 16.67 |
| Support Level | $16.06 | N/A |
| Resistance Level | $19.71 | $12.85 |
| Average True Range (ATR) | 0.74 | 0.56 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 46.23 | 13.33 |
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.